The NIH is enrolling a 50+ patient trial. ASH is expensive (biopsies, etc.). This is a trial that is costing the NIH several $millions. To suggest that the trial was simply "rubber stamped" because of the PI is nonsensical. These things are reviewed by committees, the key criteria being scientific merit and potential impact on patients.
BTW - The NIH ran Intercept's Phase II trial (FLINT). Just saying.
"The FLINT trial (Clinical Trials No. NCT01265498(link is external)) was supported by the NIDDK, National Cancer Institute and National Center for Advancing Translational Sciences, all part of NIH. Intercept Pharmaceuticals, Inc. provided partial funding and supplies."
- Forums
- ASX - By Stock
- Ann: Appendix 4D - Half Yearly Report and Accounts
The NIH is enrolling a 50+ patient trial. ASH is expensive...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMC (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $23.93M |
Open | High | Low | Value | Volume |
10.5¢ | 10.5¢ | 10.0¢ | $18.24K | 181.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 133830 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 166666 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 133830 | 0.100 |
1 | 40000 | 0.099 |
1 | 45503 | 0.098 |
2 | 150000 | 0.097 |
1 | 3934 | 0.095 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 166666 | 3 |
0.110 | 232704 | 4 |
0.120 | 8695 | 1 |
0.125 | 53748 | 2 |
0.130 | 71546 | 4 |
Last trade - 12.45pm 01/10/2024 (20 minute delay) ? |
Featured News
IMC (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online